Peptides for Testosterone: Can Peptides Support Natural T Levels?

Key Takeaways

• Compounds covered: Kisspeptin, gonadorelin, CJC-1295, ipamorelin, sermorelin
• Goal area: HPG axis pharmacology and GH/IGF-1 axis physiology relevant to testosterone
• Evidence range: Ranges from published human pharmacodynamic studies with measured LH/FSH/testosterone endpoints in healthy men and some men with mild hypogonadism (kisspeptin) to pharmacokinetic and dose-finding studies (CJC-1295, ipamorelin) and clinical pharmacology reviews (sermorelin). None has completed a Phase III efficacy trial for hypogonadism treatment or testosterone-associated endpoints.
• Regulatory range: None of these compounds is FDA-approved for testosterone support. Kisspeptin, CJC-1295, and ipamorelin are not on FDA's positive 503A bulk drug substances list; CJC-1295 and ipamorelin are on FDA's Category 2 interim bulks list, reflecting safety and characterization concerns. Sermorelin has a distinct history tied to Geref's prior FDA approval and subsequent commercial withdrawal. Pharmacies that compound these substances do so outside the 503A safe harbor and accept the associated FDA enforcement risk, which FDA has not formally endorsed.
• Controlled substance context: Testosterone itself (TRT) is a Schedule III controlled substance under the Controlled Substances Act. TRT is not a peptide and is not the subject of this article.
• Key biomarkers for testosterone: Total testosterone, free testosterone, LH, FSH, SHBG, estradiol, IGF-1, prolactin
• As of April 2026: Kisspeptin is not FDA-approved for any indication. No peptide discussed here is FDA-approved for testosterone support.
• Bottom line: Kisspeptin is the only compound in this article with published human pharmacodynamic data on testosterone as a measured endpoint; GH secretagogues are studied for effects on GH/IGF-1 and body composition rather than direct testosterone stimulation. All framing in this article is educational, not a recommendation for use.

Understanding Testosterone Regulation: The Biology

Testosterone production in men is governed by the hypothalamic-pituitary-gonadal (HPG) axis — a hierarchical signaling system that operates through sequential hormonal cascades. The process begins in the hypothalamus, where kisspeptin neurons project onto GnRH (gonadotropin-releasing hormone) neurons and drive their pulsatile release. GnRH travels via the portal blood supply to the anterior pituitary, where it stimulates the production and release of LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH acts on Leydig cells in the testes to drive testosterone biosynthesis from cholesterol. Testosterone circulates partially bound to sex hormone-binding globulin (SHBG) and albumin; the unbound fraction (free testosterone) is biologically active at target tissues.

Salonia and colleagues' 2019 review in Nature Reviews Disease Primers documented male hypogonadism comprehensively, including both organic causes (structural pituitary or testicular pathology) and functional causes (obesity, chronic illness, aging, metabolic disruption). Functional hypogonadism — low testosterone with low or inappropriately normal LH/FSH — is where peptide-based HPG axis pharmacology has been most studied, because the pathway is intact and suppressed rather than structurally damaged. Corona and colleagues' 2020 European Academy of Andrology guidelines characterize functional hypogonadism as a category in which non-TRT approaches, including investigational upstream HPG stimulation, have mechanistic rationale.

Kisspeptin occupies the top of the HPG axis hierarchy and is the primary upstream activator of the GnRH pulse generator. Xie and colleagues' 2022 review describes kisspeptin as master upstream GnRH regulator and therefore of the entire HPG axis. George and colleagues' 2010 Neuroendocrinology hypothesis paper proposed kisspeptin's role in male hypogonadism in obesity and type 2 diabetes, contextualizing the demographic in which kisspeptin pharmacology has been studied.

Growth hormone secretagogues interact with a parallel axis — the GH/IGF-1 system — which supports body composition, muscle mass, fat metabolism, and metabolic function. Hobbs, Plymate, and Rosen, in 1993, reported in the Journal of Clinical Endocrinology and Metabolism that testosterone administration increased IGF-1 in men — one direction of the T/IGF-1 relationship. GH secretagogues elevate IGF-1 through pituitary GH stimulation; whether this translates to testosterone elevation is indirect, operating through body composition and metabolic effects on testosterone-associated physiology rather than through direct testosterone stimulation.

Controlled substance context for TRT: Testosterone is a Schedule III controlled substance under the Controlled Substances Act (21 U.S.C. § 812). TRT therefore requires a DEA-registered prescriber and is subject to controlled-substance prescribing, telehealth (Ryan Haight Act), and state monitoring requirements that do not apply to non-controlled prescription peptides. Testosterone itself is not a peptide; the peptides discussed in this article are distinct from TRT and are not direct substitutes.

Peptides Studied in HPG / GH Axis Pharmacology: A Quick Comparison

The following peptides have published evidence relevant to HPG axis or GH/IGF-1 axis pharmacology. They are listed by directness and strength of evidence for testosterone outcomes specifically. Regulatory status descriptions reflect FDA posture as of April 2026.

• Compound: Kisspeptin (kisspeptin-10, kisspeptin-54)
  Mechanism in HPG physiology: Stimulates GnRH release from hypothalamus via KISS1R agonism; drives LH and FSH; stimulates Leydig cell testosterone production
  Evidence: Published pharmacodynamic human studies with measured LH, FSH, and testosterone endpoints in healthy men and in some men with mild hypogonadism. Not a completed Phase III hypogonadism efficacy trial.
  FDA status: Not FDA-approved for any indication. Not on FDA's positive 503A bulks list; the substance does not satisfy the statutory criteria for lawful 503A compounding under 21 U.S.C. § 353a(b)(1)(A), and some pharmacies compound it on the basis of patient-specific prescriptions and accept the associated FDA enforcement risk, which FDA has not formally endorsed.
  Route: Subcutaneous or intravenous in investigational/research settings
• Compound: Gonadorelin (synthetic GnRH decapeptide)
  Mechanism in HPG physiology: Acts at the pituitary downstream of kisspeptin to stimulate LH and FSH release, which in turn can drive testicular testosterone production
  Evidence: Historical FDA approval (Factrel, Lutrepulse — both withdrawn for commercial reasons, not for safety or efficacy); used in some clinical protocols to preserve HPG axis function
  FDA status: No currently marketed FDA-approved gonadorelin product following commercial withdrawal of Factrel and Lutrepulse. Under 21 U.S.C. § 353a(b)(1)(A)(i), a bulk drug substance that is a component of an FDA-approved drug qualifies for 503A compounding; whether gonadorelin's prior approvals (since withdrawn for commercial reasons) satisfy this criterion for current 503A compounding is an active interpretive question that FDA has not definitively resolved, and pharmacy practice varies. Use for testosterone-associated physiology is off-label.
  Route: Subcutaneous injection
• Compound: CJC-1295 (GHRH analog)
  Mechanism: Stimulates pituitary GH release; elevates IGF-1; influences body composition in some studies of hypogonadal men; indirect effect on testosterone-associated physiology rather than on testosterone directly
  Evidence: Phase II pharmacokinetic/pharmacodynamic trials demonstrating sustained GH and IGF-1 elevation; body composition data in hypogonadal men
  FDA status: Not FDA-approved. Placed on FDA's Category 2 interim bulks list, reflecting safety and characterization concerns. 503A compounding of CJC-1295 occurs under FDA enforcement-discretion risk, not under an affirmed statutory pathway.
  Route: Subcutaneous injection
• Compound: Ipamorelin (GHRP)
  Mechanism: Selective GHRP-receptor agonist that stimulates GH release without significantly raising cortisol or prolactin in published human studies; elevates IGF-1
  Evidence: Animal studies establishing selectivity; Phase I/II human data on GH release
  FDA status: Not FDA-approved. Placed on FDA's Category 2 interim bulks list. 503A compounding of ipamorelin occurs under FDA enforcement-discretion risk.
  Route: Subcutaneous injection
• Compound: Sermorelin (GHRH analog)
  Mechanism: GHRH analog that stimulates pituitary GH release; elevates IGF-1; associated with body composition and metabolic endpoints in older adults in some studies
  Evidence: Clinical pharmacology data from prior FDA-approved formulations (Geref therapeutic; Geref Diagnostic); observational data in older men on body composition and metabolic endpoints
  FDA status: Sermorelin acetate was previously FDA-approved for therapeutic use (Geref, pediatric GH deficiency) and as a diagnostic agent (Geref Diagnostic); both were commercially withdrawn. Sermorelin's continued eligibility as a 503A bulk based on its prior-approval history has been discussed by FDA and is not definitively settled for all formulations. Use for testosterone-associated physiology is off-label.
  Route: Subcutaneous injection

Peptides Studied in HPG / GH Axis Pharmacology: Individual Profiles

Each compound approaches HPG or GH/IGF-1 physiology through a distinct mechanism. The evidence bases differ substantially — from published human pharmacodynamic data with measured testosterone endpoints to indirect body composition effects via the GH/IGF-1 axis. Each requires independent evaluation.

Kisspeptin

Kisspeptin is an endogenous neuropeptide — the product of the KISS1 gene — that acts as the master upstream regulator of the HPG axis. As an investigational compound, kisspeptin agonizes hypothalamic KISS1R to stimulate pulsatile GnRH release, creating a physiological cascade that drives LH and FSH from the pituitary and ultimately Leydig cell testosterone synthesis in the testes.

Dhillo and colleagues published the first human study in 2005 in the Journal of Clinical Endocrinology and Metabolism, reporting kisspeptin-54 effects on LH, FSH, testosterone in healthy male volunteers following a single dose. Jayasena and colleagues, writing in the same journal in 2011, reported that kisspeptin-10 stimulated LH and increased both pulse frequency and amplitude, establishing the shorter, more pharmacologically stable fragment as relevant for investigational administration. George and colleagues' 2013 Clinical Endocrinology study reported kisspeptin-10 pharmacodynamic responses in men with type 2 diabetes and mild hypogonadism. These findings are preliminary and do not establish clinical efficacy for hypogonadism treatment.

Skorupskaite and colleagues' 2014 review in Human Reproduction Update characterizes kisspeptin as HPG therapeutic target and diagnostic biomarker. Chan and colleagues, in a 2014 Journal of Clinical Endocrinology and Metabolism paper, used kisspeptin as GnRH neuronal probe in patients with idiopathic hypogonadotropic hypogonadism — relevant to patient selection, since structural hypogonadism (damaged pituitary or testes) would not be expected to respond to upstream HPG stimulation. [Published pharmacodynamic human studies with measured testosterone endpoints; no completed Phase III hypogonadism efficacy trial]

Kisspeptin is not FDA-approved for any indication. It is not currently on FDA's positive 503A bulk drug substances list. Some 503A pharmacies compound kisspeptin on the basis of patient-specific prescriptions; FDA has not formally affirmed this practice, and access varies by state and pharmacy. Ide and colleagues' 2020 International Journal of Molecular Sciences review reviews kisspeptin among investigational alternatives to TRT for central hypogonadism. Clinical protocols vary; any investigational use would be individualized by a licensed prescriber based on baseline HPG axis evaluation.

Gonadorelin

Gonadorelin is a synthetic decapeptide identical in sequence to endogenous GnRH. It acts at the anterior pituitary downstream of kisspeptin to stimulate LH and FSH release, which in turn drives testicular testosterone production. Gonadorelin was previously FDA-approved under the brand names Factrel (diagnostic) and Lutrepulse (for the induction of ovulation in women with hypothalamic amenorrhea); both products were commercially withdrawn, not withdrawn for safety or efficacy reasons.

In some clinical protocols, gonadorelin is used to preserve HPG axis function during or after exogenous androgen exposure. Its use for testosterone-associated physiology in men is off-label. Because Factrel and Lutrepulse are no longer commercially marketed, current access to gonadorelin is through 503A compounding. Under 21 U.S.C. § 353a(b)(1)(A)(i), a bulk drug substance that is a component of an FDA-approved drug qualifies for 503A compounding; whether gonadorelin's prior approvals (since withdrawn for commercial reasons) satisfy this criterion is an active interpretive question that FDA has not definitively resolved, and pharmacy practice varies. [Prior FDA-approved formulations withdrawn for commercial reasons; off-label use for testosterone-associated physiology]

CJC-1295

CJC-1295 is a synthetic GHRH (growth hormone-releasing hormone) analog. A version with a drug affinity complex (DAC) modification binds serum albumin and extends half-life to several days, enabling less frequent dosing than native GHRH. Its primary mechanism is stimulation of pituitary somatotrophs to release growth hormone, which drives hepatic IGF-1 production.

Teichman and colleagues, writing in the Journal of Clinical Endocrinology and Metabolism in 2006, reported CJC-1295 sustained GH and IGF-1 increases lasting more than six days from a single injection in healthy adults. Ionescu and Frohman, in a 2006 Journal of Clinical Endocrinology and Metabolism paper, reported that pulsatile GH secretion persists with CJC-1295 in healthy adults.

CJC-1295 does not directly stimulate testosterone production. Its relevance to testosterone-associated physiology is through IGF-1 elevation and effects on the downstream body composition and metabolic physiology reported in GH-axis research. Sinha and colleagues' 2020 review in Translational Andrology and Urology reviews GH secretagogues in performance-enhancement contexts. Sigalos and Pastuszak's 2017 American Journal of Men's Health paper reports IGF-1 elevation in hypogonadal men. [Phase II pharmacokinetics; body composition evidence in hypogonadal population]

FDA's Pharmacy Compounding Advisory Committee has reviewed CJC-1295 and placed it on FDA's Category 2 interim bulks list, reflecting safety, quality, and characterization concerns (including risk of immunogenicity, impurities from peptide synthesis, and uncharacterized long-acting pharmacology). FDA has not authorized CJC-1295 for 503A compounding. Pharmacies that compound CJC-1295 do so under FDA enforcement-discretion risk.

Ipamorelin

Ipamorelin is a synthetic growth hormone-releasing peptide (GHRP) that selectively agonizes the ghrelin receptor (GHS-R1a) in the pituitary to stimulate GH release. Its defining characteristic in published studies is selectivity: unlike earlier GHRPs, ipamorelin did not significantly raise cortisol, prolactin, or ACTH at therapeutic doses in preclinical animal studies and limited Phase I/II human data — a profile clinically relevant because cortisol elevation can interact with HPG axis physiology.

Raun and colleagues, writing in the European Journal of Endocrinology in 1998, characterized ipamorelin's core pharmacological profile: ipamorelin as a selective growth hormone secretagogue, releasing GH with potency comparable to earlier GHRPs without the cortisol and prolactin elevations. Johansen and colleagues' 1999 paper in Growth Hormone and IGF Research reported ipamorelin longitudinal bone growth in rats. [Animal studies establishing selectivity; Phase I/II human GH release data]

A 2002 JAMA randomized controlled trial by Blackman and colleagues studied exogenous GH and testosterone in older adults and reported body composition effects. That study did not evaluate ipamorelin, CJC-1295, or kisspeptin; extrapolation from the Blackman findings to compounded peptide combinations is not supported by that trial.

Ipamorelin was reviewed at FDA's Pharmacy Compounding Advisory Committee and placed on FDA's Category 2 interim bulks list. FDA has not authorized ipamorelin for 503A compounding. Any 503A compounding of ipamorelin occurs under FDA enforcement-discretion risk rather than under an affirmed statutory pathway.

Sermorelin

Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH, which constitutes the biologically active fragment responsible for pituitary GH stimulation. Sermorelin acetate was FDA-approved for therapeutic use as Geref (pediatric GH deficiency, originally approved 1990) and was also approved as a diagnostic agent (Geref Diagnostic). Both were commercially withdrawn, not withdrawn for safety or efficacy reasons. Prakash and Goa's 1999 review in BioDrugs describes sermorelin in pediatric GH deficiency diagnosis and treatment.

For testosterone-associated physiology, Khorram and colleagues' 1997 Journal of Clinical Endocrinology and Metabolism study reported long-term GHRH-analog effects in older adults, including sustained GH and IGF-1 increases with changes in body composition and metabolic markers. [Prior FDA-approved formulations (withdrawn for commercial reasons); body composition and metabolic marker findings in older adults]

Sermorelin's continued eligibility as a 503A bulk drug substance based on its prior-approval history has been discussed by FDA; the FDA's position on this eligibility has not been definitively settled for all formulations. 503A pharmacies do compound sermorelin, but eligibility is not uniformly confirmed. Use for testosterone-associated physiology is off-label. The safety and efficacy of compounded sermorelin for this indication have not been established through adequate and well-controlled clinical trials.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry the following regulatory statuses. Testosterone itself (TRT) is a Schedule III controlled substance under the Controlled Substances Act and is not a peptide; it is referenced here only for comparative context.

• Kisspeptin: Not FDA-approved for any indication. Not on FDA's positive 503A bulks list. Some 503A pharmacies compound kisspeptin on the basis of patient-specific prescriptions; FDA has not formally affirmed this practice.
• Gonadorelin: No currently marketed FDA-approved product (Factrel and Lutrepulse were withdrawn for commercial reasons, not for safety or efficacy reasons). Under 21 U.S.C. § 353a(b)(1)(A)(i), a bulk drug substance that is a component of an FDA-approved drug qualifies for 503A compounding; whether gonadorelin's prior approvals satisfy this criterion is an active interpretive question FDA has not definitively resolved. Use for testosterone-associated physiology is off-label.
• CJC-1295: Not FDA-approved. On FDA's Category 2 interim bulks list. 503A compounding occurs under FDA enforcement-discretion risk, not under an affirmed statutory pathway.
• Ipamorelin: Not FDA-approved. On FDA's Category 2 interim bulks list. 503A compounding occurs under FDA enforcement-discretion risk.
• Sermorelin: Previously FDA-approved (Geref therapeutic; Geref Diagnostic); both commercially withdrawn. 503A eligibility based on prior-approval history has been discussed by FDA and is not definitively settled for all formulations. Use for testosterone-associated physiology is off-label.

Considerations When Comparing Peptides for Testosterone

These compounds operate through different pathways and have been studied in different populations with different endpoints. Comparing them directly as "more or less effective for testosterone" misrepresents what the evidence shows.

The specific mechanism of low testosterone: Central hypogonadism (low LH/FSH with low testosterone, where the problem is upstream HPG suppression) has been the population in which kisspeptin pharmacology has been investigated. If LH and FSH are elevated with low testosterone, the testes are not responding, and upstream HPG stimulation would not be expected to help. A provider cannot determine which approach is appropriate without reviewing LH and FSH alongside testosterone.

Existing biomarker profile: IGF-1 levels, metabolic markers, body composition, and the presence of insulin resistance all affect which compound or combination a provider would evaluate. A man with low testosterone, low IGF-1, and significant visceral adiposity presents a different clinical picture than one with low testosterone and normal GH axis function.

Evidence level: Kisspeptin is the only compound in this article with published human pharmacodynamic data on testosterone as a measured endpoint. CJC-1295 and ipamorelin have published human pharmacokinetic data but not direct human data for testosterone as a primary endpoint. Sermorelin has established clinical pharmacology but limited large-scale RCT evidence for testosterone outcomes specifically. Direct comparison between these compounds is not supported by the evidence — they have been studied using different designs, populations, and endpoints. Inferring relative effectiveness from separate trials is methodologically unreliable.

Fertility considerations: Exogenous testosterone (TRT) can suppress LH and FSH during use and affect spermatogenesis per its FDA-approved label. Kisspeptin acts upstream at the GnRH pulse generator in investigational pharmacodynamic studies; whether sustained kisspeptin administration preserves spermatogenesis in clinical use has not been established in adequate trials, and direct comparative fertility outcomes versus TRT have not been studied. Any fertility goals should be discussed with a licensed reproductive endocrinologist, not decided on the basis of mechanism or indirect comparison.

Controlled substance context: TRT is a Schedule III controlled substance and is subject to the Controlled Substances Act, Ryan Haight Act, and state controlled-substance monitoring. The peptides discussed here are not controlled substances; they are separately regulated under the FD&C Act and FDA's 503A compounding framework. This difference affects the prescribing pathway but does not bear on which intervention is clinically appropriate for any specific individual.

Route and protocol preferences: All compounds in this list require subcutaneous injection (kisspeptin may also be administered intravenously in research settings). Frequency, timing, and duration protocols vary by compound and clinical context. These are practical considerations for prescriber-patient discussion.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full HPG axis lab panel, medical history, and current medications before recommending any compound.

Safety Considerations

Safety profiles across this compound class reflect different mechanisms and different evidence depths. None of these compounds has completed Phase III clinical trials for testosterone support specifically, meaning side effect profiles are informed by smaller studies and clinical experience rather than large-scale safety monitoring.

GH secretagogues (CJC-1295, ipamorelin, sermorelin) can elevate IGF-1 levels outside the reference range with excessive dosing. IGF-1 monitoring is often performed by prescribing providers during GH secretagogue protocols to track response and safety. Fluid retention, joint discomfort, and carpal tunnel symptoms have been reported with GH elevation across compound classes. Ipamorelin's selectivity profile means cortisol and prolactin elevation are less likely than with earlier GHRPs, but not impossible at high doses.

Kisspeptin interacts with the HPG axis; in published human studies, effects on LH pulsatility and testosterone have been reported to be dose- and timing-dependent. As of April 2026, no completed human efficacy and safety trials for kisspeptin in male hypogonadism treatment have been published beyond short-term pharmacodynamic data; long-term safety is not established.

Contraindications that apply broadly to peptide therapy discussed in this article include:

• Active hormone-sensitive malignancy — including prostate cancer; HPG axis stimulation (whether through kisspeptin, LH-FSH-stimulating peptides, or other mechanisms) can raise testosterone, which can drive hormone-sensitive cancers. PSA and prostate evaluation are standard pre-treatment assessment for any testosterone-increasing intervention, including the FDA-approved framework established by the 2018 Endocrine Society clinical practice guideline by Bhasin and colleagues for TRT; analogous pre-treatment oncological clearance is recommended before any investigational compound that could increase testosterone.
• Structural hypogonadism (primary hypogonadism with elevated LH/FSH) — kisspeptin and GHRH analogs would not be expected to restore testosterone production when the testes or pituitary have structural damage; the appropriate approach differs.
• Pregnancy — not applicable as a primary indication, but relevant for female partners of men considering investigational protocols.
• Active pituitary adenoma or hypothalamic disease — upstream HPG stimulation requires an intact pathway to produce the intended effect.
• Use without provider evaluation and baseline labs — initiating HPG axis stimulation without establishing the cause of low testosterone creates risk of treating the wrong mechanism.

For compound-specific side effect profiles, consult individual compound literature and a licensed healthcare provider familiar with your health history.

What to Test Before Discussing Peptides for Testosterone

Baseline HPG axis testing is not optional before any testosterone-related conversation — it is the data that determines whether any investigational approach is mechanistically appropriate. Without LH and FSH alongside total testosterone, a provider cannot distinguish the type of hypogonadism or identify the most rational evaluation.

• Total testosterone: The primary clinical testosterone measurement. Testing total testosterone establishes the baseline and confirms whether deficiency exists. Reference ranges vary by lab and age — interpretation requires clinical context.
• Free testosterone: The biologically active fraction not bound to SHBG or albumin. Free testosterone can be clinically low even when total testosterone appears borderline, particularly when SHBG is elevated.
• LH (luteinizing hormone): The pituitary signal that drives testosterone production. LH levels distinguish central hypogonadism (low LH with low testosterone) from primary hypogonadism (elevated LH with low testosterone, where the testes are the problem).
• FSH (follicle-stimulating hormone): Pairs with LH to complete the pituitary gonadotropin picture. Testing FSH alongside LH is standard for HPG axis evaluation and for assessing fertility implications.
• SHBG (sex hormone-binding globulin): Determines how much testosterone is bioavailable. Elevated SHBG reduces free testosterone even when total testosterone is normal. Age, thyroid function, and liver health all influence SHBG levels.
• Estradiol: Aromatization of testosterone to estradiol is regulated by body fat and enzyme activity. Testing estradiol establishes the T:E2 ratio and identifies whether aromatization is contributing to low free testosterone or symptomatic changes.
• IGF-1: The primary downstream marker of GH axis activity. Testing IGF-1 is relevant if GH secretagogues are being considered, and establishes whether GH axis activity is contributing to body composition symptoms alongside testosterone changes.
• Prolactin: Elevated prolactin suppresses GnRH and LH, causing secondary hypogonadism. A prolactin baseline screens for hyperprolactinemia as a reversible and treatable cause of HPG suppression.

Total testosterone, free testosterone, LH, FSH, SHBG, and estradiol together constitute the complete HPG axis baseline. Without these values before any conversation, changes over time have no reference point to compare against. Superpower's testosterone and hormonal biomarker guide covers these markers in detail.

How to Approach These Peptides Safely

The peptides discussed in this article are investigational or compounded under varying regulatory postures; none is FDA-approved for testosterone support. Any conversation about investigational use should occur with a licensed prescriber who has reviewed your medical history, symptoms, and baseline lab results. Compounded products from 503A pharmacies are also not FDA-approved and carry different regulatory status than approved drugs.

For any man evaluating low testosterone, the appropriate starting point is a complete HPG axis evaluation with a licensed provider. Sports medicine physicians, endocrinologists, urologists, and primary care physicians experienced in hormone evaluation can characterize the specific type of hypogonadism and recommend the evidence-based approach for that clinical picture. FDA-approved therapies (including TRT, which is a Schedule III controlled substance) have substantially more human evidence than the peptides discussed here.

Products sold online as injectable "testosterone-support peptides" outside a prescriber relationship lack the clinical evaluation that distinguishes a physiologically appropriate intervention from one that targets the wrong mechanism, and they lack the manufacturing oversight of regulated pharmacies. Contamination and dosing inconsistency are documented risks in this product category.

Understanding Your Baseline

With multiple peptides studied at different points in the HPG axis and the parallel GH/IGF-1 system — each with different evidence depths and regulatory postures — baseline biomarker data is what transforms a conversation with your provider from "which peptide should I try for testosterone" to "what does my hormone physiology actually show." The distinction between central and primary hypogonadism, between low free testosterone from elevated SHBG and low testosterone from HPG suppression, between GH axis deficiency and HPG axis suppression — none of these is visible without lab data.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to an FDA-approved therapy, a lifestyle intervention, or continued evaluation, the starting point is the same: knowing what your HPG axis actually shows.

IMPORTANT SAFETY INFORMATION

Kisspeptin is not FDA-approved for any indication. It is not on FDA's positive 503A bulk drug substances list; the substance does not satisfy the statutory criteria for lawful 503A compounding under 21 U.S.C. § 353a(b)(1)(A), and pharmacies that compound it do so outside the 503A safe harbor and accept the associated FDA enforcement risk, which FDA has not formally endorsed. As a compounded drug, it is not the same as any FDA-approved product. The safety, efficacy, and optimal dosing of compounded kisspeptin for hypogonadism or testosterone support have not been established through adequate and well-controlled clinical trials.

CJC-1295 is not FDA-approved for any indication. FDA's Pharmacy Compounding Advisory Committee has reviewed CJC-1295 and placed it on FDA's Category 2 interim bulks list, reflecting safety, quality, and characterization concerns. FDA has not authorized CJC-1295 for 503A compounding. As a compounded GHRH analog, it is not the same as any FDA-approved growth hormone or GHRH product. The safety and efficacy of compounded CJC-1295 for testosterone-associated physiology have not been established through large-scale randomized controlled trials. IGF-1 monitoring is often performed by prescribing providers during GH secretagogue protocols.

Ipamorelin is not FDA-approved for any indication. Ipamorelin has been reviewed at FDA's Pharmacy Compounding Advisory Committee and placed on FDA's Category 2 interim bulks list. FDA has not authorized ipamorelin for 503A compounding. Safety profile is based on preclinical selectivity studies and limited human pharmacodynamic data rather than Phase III clinical safety trials. Monitoring for IGF-1 elevation is often performed during GH secretagogue protocols.

Sermorelin (sermorelin acetate) was FDA-approved for therapeutic use (Geref, pediatric GH deficiency) and as a diagnostic agent (Geref Diagnostic). Both were commercially withdrawn, not withdrawn for safety or efficacy reasons. Sermorelin's continued eligibility as a 503A bulk drug substance based on its prior-approval history has been discussed by FDA; the FDA's position on this eligibility has not been definitively settled for all formulations. Use for testosterone-associated physiology is off-label. The safety and efficacy for this use have not been established through adequate and well-controlled clinical trials.

Gonadorelin was previously FDA-approved (Factrel, Lutrepulse) and both products were commercially withdrawn, not withdrawn for safety or efficacy reasons. Under 21 U.S.C. § 353a(b)(1)(A)(i), a bulk drug substance that is a component of an FDA-approved drug qualifies for 503A compounding; whether gonadorelin's prior approvals satisfy this criterion is an active interpretive question FDA has not definitively resolved. Use for testosterone-associated physiology is off-label.

Testosterone itself (TRT) is a Schedule III controlled substance under the Controlled Substances Act (21 U.S.C. § 812). Testosterone is not a peptide. Any prescription for TRT must be issued by a DEA-registered prescriber and is subject to controlled-substance prescribing, telehealth (Ryan Haight Act), and state monitoring requirements distinct from non-controlled prescription peptides.

Contraindications applicable across the compound class discussed here include active hormone-sensitive malignancy (particularly prostate cancer — testosterone elevation may stimulate growth); structural hypogonadism or pituitary pathology where upstream HPG stimulation would not produce the intended effect; active psychiatric conditions affecting the HPG axis; and concurrent use of medications affecting GnRH, LH/FSH, or testosterone metabolism without prescriber review.

Common side effects reported across GH secretagogue classes include injection site reactions, transient water retention, joint discomfort, and fatigue at initiation. Kisspeptin's side effect profile in longer-term protocols has not been fully characterized. No compound discussed in this article should be used without a licensed provider relationship and baseline laboratory evaluation.

As of April 2026, no completed Phase III clinical efficacy and safety trials for any peptide discussed in this article specifically for male hypogonadism or testosterone support have been published. Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses peptide compounds with different regulatory statuses. None is FDA-approved for testosterone support. Some do not satisfy the statutory criteria for lawful 503A compounding; pharmacies that compound them do so outside the 503A safe harbor and accept the associated FDA enforcement risk, which FDA has not formally endorsed. This educational content is editorially independent and is not a recommendation to use any compound discussed.